4D Molecular Therapeutics (FDMT) Revenue & Revenue Breakdown
4D Molecular Therapeutics Revenue Highlights
Main Segment (Y)
Collaboration And License Revenue
Main Geography (Y)
JAPAN
4D Molecular Therapeutics Revenue by Period
4D Molecular Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2025-12-31 | - | -100.00% |
| 2024-12-31 | $37.00K | -99.82% |
| 2023-12-31 | $20.72M | 562.29% |
| 2022-12-31 | $3.13M | -82.65% |
| 2021-12-31 | $18.04M | 32.52% |
| 2020-12-31 | $13.61M | 94.85% |
| 2019-12-31 | $6.99M | -50.56% |
| 2018-12-31 | $14.13M | 144.04% |
| 2017-12-31 | $5.79M | - |
4D Molecular Therapeutics generated - in revenue during NA 2025, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
4D Molecular Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2026-03-31 | - | -100.00% |
| 2025-12-31 | $85.09M | 94444.44% |
| 2025-09-30 | $90.00K | 500.00% |
| 2025-06-30 | $15.00K | 7.14% |
| 2025-03-31 | $14.00K | 1300.00% |
| 2024-12-31 | $1.00K | -66.67% |
| 2024-09-30 | $3.00K | -40.00% |
| 2024-06-30 | $5.00K | -82.14% |
| 2024-03-31 | $28.00K | -247.37% |
| 2023-12-31 | $-19.00K | -100.09% |
| 2023-09-30 | $20.20M | 8353.56% |
| 2023-06-30 | $239.00K | -19.80% |
| 2023-03-31 | $298.00K | -76.10% |
| 2022-12-31 | $1.25M | 149.40% |
| 2022-09-30 | $500.00K | 208.64% |
| 2022-06-30 | $162.00K | -86.71% |
| 2022-03-31 | $1.22M | 1225.00% |
| 2021-12-31 | $92.00K | -93.27% |
| 2021-09-30 | $1.37M | -90.63% |
| 2021-06-30 | $14.58M | 629.00% |
| 2021-03-31 | $2.00M | -304.71% |
| 2020-12-31 | $-977.00K | -113.17% |
| 2020-09-30 | $7.42M | 104.27% |
| 2020-06-30 | $3.63M | 2.77% |
| 2020-03-31 | $3.54M | 74.14% |
| 2019-12-31 | $2.03M | 275.93% |
| 2019-09-30 | $540.00K | -75.54% |
| 2019-06-30 | $2.21M | - |
| 2019-03-31 | $2.21M | -51.26% |
| 2018-12-31 | $4.53M | - |
| 2018-09-30 | $4.53M | 78.75% |
| 2018-06-30 | $2.53M | - |
| 2018-03-31 | $2.53M | - |
4D Molecular Therapeutics generated - in revenue during Q1 2026, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
4D Molecular Therapeutics Revenue Breakdown
4D Molecular Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Collaboration And License Revenue | $85.21M | $37.00K | $20.01M | $3.13M | $18.04M |
4D Molecular Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 25: Collaboration And License Revenue (100.00%).
Quarterly Revenue by Product
| Product/Service | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaboration And License Revenue | $3.05M | $85.09M | $90.00K | $15.00K | $14.00K | $6.00K | $3.00K | $28.00K | - | $20.01M | $239.00K | $298.00K | $1.25M | $500.00K | $162.00K | $1.22M | $12.00K | $64.00K | $14.58M | $2.00M |
4D Molecular Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Mar 26: Collaboration And License Revenue (100.00%).
4D Molecular Therapeutics Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| JAPAN | $85.00M | - | - | - | - |
| UNITED STATES | $209.00K | $37.00K | $20.16M | $35.00K | $121.00K |
| NETHERLANDS | - | - | $567.00K | $3.09M | $736.00K |
| SWITZERLAND | - | - | - | - | $17.18M |
4D Molecular Therapeutics's latest annual revenue breakdown by geography, as of Dec 25: JAPAN (99.75%), and UNITED STATES (0.25%).
Quarterly Revenue by Country
| Country | Mar 26 | Dec 24 | Sep 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UNITED STATES | $90.00K | $6.00K | $3.00K | $28.00K | - | $20.16M | $9.00K | $3.00K | $2.00K | $3.00K | $2.00K | $28.00K | $89.00K | $12.00K | $16.00K | $3.00K |
| JAPAN | $2.96M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| NETHERLANDS | - | - | - | - | $1.00K | $41.00K | $230.00K | $295.00K | $1.25M | $497.00K | $160.00K | $1.19M | $12.00K | $64.00K | $267.00K | $392.00K |
| SWITZERLAND | - | - | - | - | - | - | - | - | - | - | - | - | $-9.00K | $1.29M | $14.30M | $1.60M |
4D Molecular Therapeutics's latest quarterly revenue breakdown by geography, as of Mar 26: JAPAN (97.05%), and UNITED STATES (2.95%).
4D Molecular Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| RGNX | REGENXBIO | $170.44M | $6.39M |
| ADCT | ADC Therapeutics | $73.55M | $20.85M |
| BCYC | Bicycle Therapeutics | $72.59M | $887.00K |
| LXRX | Lexicon Pharmaceuticals | $49.80M | $21.10M |
| GOSS | Gossamer Bio | $48.47M | $16.95M |
| PRTA | Prothena | $9.68M | $51.08M |
| CMPX | Compass Therapeutics | - | - |
| FDMT | 4D Molecular Therapeutics | - | - |
| KALV | KalVista Pharmaceuticals | - | $59.92M |
| NMRA | Neumora Therapeutics | - | - |
| OMER | Omeros | - | - |